This product is for research use only, not for human use. We do not sell to patients.
| Size | Price |
|---|---|
| 250mg | Get quote |
| 500mg | Get quote |
| 1g | Get quote |
: Cat #: V3814 CAS #: 1200493-78-2 (free base) Purity ≥ 98%
Description: Atabecestat HCl (formerly known as JNJ-54861911 HCl), the hydrochloride salt of Atabecestat, is a novel potent, oral, and brain-penetrant inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is an enzyme that is up-regulated in Alzheimer's disease. β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer's disease (AD), but treatment initiation may need to be very early. JNJ-54861911 was found to inhibit BACE1 with approximately 2,600 nM affinity to 1 nM affinity. JNJ-54861911 was well-tolerated, adverse events were uncommon and unrelated to JNJ-54861911. JNJ-54861911 showed dose-proportional CSF and plasma pharmacokinetic profiles.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 403.86 |
|---|---|
| Molecular Formula | C18H15ClFN5OS |
| CAS No. | 1200493-78-2 (free base) |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 10 mM |
| Water: < 1 mg/mL | |
| Ethanol: < 1 mg/mL | |
| Synonyms | JNJ-54861911 HCl; RSC-385896 HCl; JNJ54861911 HCl; RSC 385896; JNJ 54861911; RSC385896 hydrochloride; JNJ-54861911-AAA; Atabecestat HCl |
| Protocol | In Vitro | In vitro activity: Atabecestat (formerly known as JNJ-54861911) is a novel potent, oral, and brain-penetrant inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is an enzyme that is up-regulated in Alzheimer’s disease. β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer's disease (AD), but treatment initiation may need to be very early. JNJ-54861911 was found to inhibit BACE1 with approximately 2,600 nM affinity to 1 nM affinity. JNJ-54861911 was well-tolerated, adverse events were uncommon and unrelated to JNJ-54861911. JNJ-54861911 showed dose-proportional CSF and plasma pharmacokinetic profiles. Kinase Assay: JNJ-54861911 inhibited BACE1 with IC50 of 2,600 nM to 1 nM. |
|---|
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.4761 mL | 12.3805 mL | 24.7611 mL | 49.5221 mL |
| 5mM | 0.4952 mL | 2.4761 mL | 4.9522 mL | 9.9044 mL |
| 10mM | 0.2476 mL | 1.2381 mL | 2.4761 mL | 4.9522 mL |
| 20mM | 0.1238 mL | 0.6190 mL | 1.2381 mL | 2.4761 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.